Preclinical Study Will Probe Potency of Cymerus MSCs

Preclinical Study Will Probe Potency of Cymerus MSCs

288571

Preclinical Study Will Probe Potency of Cymerus MSCs

Cynata Therapeutics will begin a preclinical study to investigate the mechanisms underlying the high potency of its cell therapy, Cymerus mesenchymal stem cells (MSCs), in treating lung diseases such as idiopathic pulmonary fibrosis (IPF). In an earlier study, the investigational therapy was able to strongly reduce IPF symptoms and improve lung function in a mouse model of the disease. Data generated in the upcoming study, which will be led by Chrishan Samuel, PhD, professor at the…

You must be logged in to read/download the full post.